These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 14760417)

  • 21. Genetic alterations of CCND1 and EMSY in breast cancers.
    Kirkegaard T; Nielsen KV; Jensen LB; Campbell FM; Müller S; Tovey SM; Brown S; Cooke TG; Bartlett JM
    Histopathology; 2008 May; 52(6):698-705. PubMed ID: 18393977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Up-regulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair.
    Song L; Dai T; Xie Y; Wang C; Lin C; Wu Z; Ying Z; Wu J; Li M; Li J
    J Mol Cell Biol; 2012 Apr; 4(2):108-17. PubMed ID: 22158906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
    Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.
    Wang Z; Zhang J; Zhang Y; Deng Q; Liang H
    Int J Mol Med; 2018 Dec; 42(6):3542-3550. PubMed ID: 30221688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EMSY copy number variation in male breast cancers characterized for BRCA1 and BRCA2 mutations.
    Navazio AS; Rizzolo P; Silvestri V; Valentini V; Zelli V; Zanna I; Masala G; Bianchi S; Tommasi S; Palli D; Ottini L
    Breast Cancer Res Treat; 2016 Nov; 160(1):181-186. PubMed ID: 27628328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcriptional regulation of the murine brca2 gene by CREB/ATF transcription factors.
    Callens N; Baert JL; Monté D; Sunesen M; Van Lint C; de Launoit Y
    Biochem Biophys Res Commun; 2003 Dec; 312(3):702-7. PubMed ID: 14680822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
    Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
    Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cell cycle-dependent regulation of the bi-directional overlapping promoter of human BRCA2/ZAR2 genes in breast cancer cells.
    Misra S; Sharma S; Agarwal A; Khedkar SV; Tripathi MK; Mittal MK; Chaudhuri G
    Mol Cancer; 2010 Mar; 9():50. PubMed ID: 20202217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations.
    Pristauz G; Petru E; Stacher E; Geigl JB; Schwarzbraun T; Tsybrovskyy O; Winter R; Moinfar F
    Histopathology; 2010 Dec; 57(6):877-84. PubMed ID: 21166701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breast-cancer risk in BRCA-mutation-negative women from BRCA-mutation-positive families.
    Katki HA; Gail MH; Greene MH
    Lancet Oncol; 2007 Dec; 8(12):1042-1043. PubMed ID: 18054868
    [No Abstract]   [Full Text] [Related]  

  • 31. A case of familial breast cancer with double heterozygosity for BRCA1 and BRCA2 genes.
    Nomizu T; Matsuzaki M; Katagata N; Kobayashi Y; Sakuma T; Monma T; Saito M; Watanabe F; Midorikawa S; Yamaguchi Y
    Breast Cancer; 2015 Sep; 22(5):557-61. PubMed ID: 23242612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.
    Lewin R; Sulkes A; Shochat T; Tsoref D; Rizel S; Liebermann N; Hendler D; Neiman V; Ben-Aharon I; Friedman E; Paluch-Shimon S; Margel D; Kedar I; Yerushalmi R
    Breast Cancer Res Treat; 2016 Jun; 157(3):511-6. PubMed ID: 27225387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of BRCA1 and BRCA2 proteins and their correlation with clinical staging in breast cancer.
    Hedau S; Batra M; Singh UR; Bharti AC; Ray A; Das BC
    J Cancer Res Ther; 2015; 11(1):158-63. PubMed ID: 25879355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines.
    Kwon WS; Rha SY; Jeung HC; Kim TS; Chung HC
    Biochem Pharmacol; 2017 Aug; 138():163-173. PubMed ID: 28431939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers.
    Rayoo M; Yan M; Takano EA; Bates GJ; Brown PJ; Banham AH; Fox SB
    J Clin Pathol; 2009 Oct; 62(10):896-902. PubMed ID: 19622517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer. Complicated supercomplexes.
    Livingston DM
    Science; 2009 May; 324(5927):602-3. PubMed ID: 19407191
    [No Abstract]   [Full Text] [Related]  

  • 37. PML protein expression in hereditary and sporadic breast cancer.
    Plevová P; Bouchal J; Fiurásková M; Foretová L; Navrátilová M; Zapletalová J; Curík R; Kubala O; Prokop J; Kolár Z
    Neoplasma; 2007; 54(4):263-8. PubMed ID: 17822314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing.
    de la Cruz J; Andre F; Harrell RK; Bassett RL; Arun B; Mathieu MC; Delaloge S; Gilcrease MZ
    Hum Pathol; 2012 Nov; 43(11):1932-9. PubMed ID: 22591913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA signatures in hereditary breast cancer.
    Murria Estal R; Palanca Suela S; de Juan Jiménez I; Egoavil Rojas C; García-Casado Z; Juan Fita MJ; Sánchez Heras AB; Segura Huerta A; Chirivella González I; Sánchez-Izquierdo D; Llop García M; Barragán González E; Bolufer Gilabert P
    Breast Cancer Res Treat; 2013 Nov; 142(1):19-30. PubMed ID: 24129975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.